Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Chuikyo Approves Optimal Use Promotion Guidelines for Repatha, Praluent
March 16, 2017
- Ex-Minister Tamura, 17 Healthcare Leaders to Launch Study Group
March 15, 2017
- MHLW to Up Ante on Drug Distribution, Launch Panel on March 29: Minister
March 15, 2017
- PMDA’s FY2017 Project Plan Sets Higher Goal for Standard Product Review
March 15, 2017
- PMDA Approves Draft Budget for FY2017
March 15, 2017
- PMDA’s Steering Committee Discusses Fines, Regulatory Revision in Wake of Kaketsuken Scandal
March 15, 2017
- Celgene Faces Biz Improvement Order over Delays in Side Effect Reporting
March 15, 2017
- Tokyo, Osaka Govts Issue Biz Improvement Order to Dealers over Fake Harvoni
March 14, 2017
- Orphan Status Withdrawn for 4 Flu Vaccines: MHLW Notification
March 13, 2017
- MHLW to Stockpile Enough Avigan for 30,000 Persons
March 13, 2017
- Drug Prices Should Be Raised for Products with Good Outcomes: Shiozaki
March 10, 2017
- Change Necessary for Ethical Drug Distribution Rules, Shiozaki Says after Fake Harvoni Fuss
March 10, 2017
- Reference Pricing on Agenda for CEFP Social Security Working Group
March 10, 2017
- NIBIOHN Looks to Spur Next-Gen Drug Development with Unique Antibody Techs, Joins Hands with 10 Companies
March 9, 2017
- MHLW to Set Up Panel on Drug Distribution after Fake Harvoni Flub, Eyes GDP Ordinance
March 8, 2017
- MHLW’s Guide to Recommend Against Prescribing Antibacterials for Colds, Diarrhea
March 8, 2017
- Tap Real-World Data for Optimal Use of High-Priced Meds: MHLW Bureau Chief
March 7, 2017
- 3 Kansai Medico Pharmacies Slapped with Biz Improvement Order over Fake Harvoni
March 7, 2017
- MHLW to Update Its Generic Roadmap in Line with Govt Target: Official
March 7, 2017
- PMDA Certified as APEC’s Training Center of Excellence for Regulatory Science
March 6, 2017
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…